supplement × Metabolic Health
Berberine for High blood sugar
Isoquinoline plant alkaloid that activates AMP-activated protein kinase (AMPK); trials show blood-glucose-lowering effects in type 2 diabetes approaching those of metformin, though GI side effects are common.
3published research: study records
14published research: findings
Not formally gradedcertainty of the research
Published research
What studies found
Berberine for High blood sugar
13 of 13 results reported a benefit, from 3 published studies.
3 studies, including a review of trials · the chart counts everything measured
- 13 reported a benefit
Colour keyReported a benefitNo clear benefitUnclearPossible harmAmber is for highlights, such as where the most research is. It never means a result was good.
- Blood sugar after meals0.94 mmol/Llower1 review of trials2019 study ↗
- Fasting blood sugar0.54 mmol/Llower1 review of trials2019 study ↗
- Blood sugar after glucose drinkFell from 10.44 to 8.12 mmol/L1 randomised trial2023 study ↗
- Long-term blood sugar (HbA1c)Fell from 6.4 to 5.43 %1 randomised trial, compared with the start of the study2023 study ↗
- Blood sugar levels (unspecified)Reported a benefitmeasurement not reportedBerberine significantly improved blood glucose levels compared to controls.1 review of trials2023 study ↗
Also measured in these studies (4)
These were measured alongside, but they are not what this condition is about.
- Blood fats (general)Reported a benefitmeasurement not reportedBerberine significantly improved blood lipids compared to controls.1 review of trials2023 study ↗
- Body measurements and compositionReported a benefitmeasurement not reportedBerberine significantly improved body parameters and composition compared to controls.1 review of trials2023 study ↗
- Bowel polyps (adenomas)Reported a benefitmeasurement not reportedBerberine significantly improved colorectal adenomas compared to controls.1 review of trials2023 study ↗
- H. pylori stomach infectionReported a benefitmeasurement not reportedBerberine significantly improved Helicobacter pylori infections compared to controls.1 review of trials2023 study ↗
3 laboratory markers also measured
- Insulin resistance · lab markerFell from 3.61 to 2.411 randomised trial, compared with the start of the study2 of 2 results reported a benefit2023 study ↗
- Fasting insulin · lab markerFell from 9.81 to 7.88 mmol/L1 randomised trial2023 study ↗
- Inflammation markers (general) · lab markerReported a benefitmeasurement not reportedBerberine significantly improved inflammatory markers compared to controls.1 review of trials2023 study ↗
Side effects: measured in 1 result. 1 result reported more side effects than the comparison group.
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every result is listed below.
See every resultWhy Berberine for High blood sugar?
The connection
Type 2 diabetes, prediabetes, insulin resistance and metabolic syndrome — where the aim is lower blood sugar.
Also known as: Berberine HCl
Published research
Berberine × High blood sugar: at a glance
Every published result for this pair, extracted and audited.
These charts count reported findings from published studies, grouped by reported benefit and study design. Study design is not a certainty grade.
Berberine / High blood sugar: reported findings; one study may contribute several findings.
What the evidence shows
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| Benefit | 13 |
| Harm / risk | 1 |
Study designs behind these findings
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| Meta-analysis | 2 |
| Systematic review | 8 |
| Randomised trial | 4 |
- Studies
- 3
| Study | Outcome | Reported result | Uncertainty (as reported) | Study duration |
|---|---|---|---|---|
| Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. (PMID 30393248) | fasting plasma glucose (FPG) | -0.54 mmol/L | 95% CI: -0.77 to -0.30 | Not reported |
| Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. (PMID 30393248) | postprandial plasma glucose (PPG) | -0.94 mmol/L | 95% CI: -1.27 to -0.61 | Not reported |
| Berberine and health outcomes: An umbrella review. (PMID 36999891) | blood glucose levels | Not reported | Not reported | Not reported |
| Berberine and health outcomes: An umbrella review. (PMID 36999891) | blood lipids | Not reported | Not reported | Not reported |
| Berberine and health outcomes: An umbrella review. (PMID 36999891) | body parameters and composition | Not reported | Not reported | Not reported |
| Berberine and health outcomes: An umbrella review. (PMID 36999891) | colorectal adenomas | Not reported | Not reported | Not reported |
| Berberine and health outcomes: An umbrella review. (PMID 36999891) | gastrointestinal symptoms | Not reported | Not reported | Not reported |
| Berberine and health outcomes: An umbrella review. (PMID 36999891) | Helicobacter pylori infections | Not reported | Not reported | Not reported |
| Berberine and health outcomes: An umbrella review. (PMID 36999891) | inflammatory markers | Not reported | Not reported | Not reported |
| Berberine and health outcomes: An umbrella review. (PMID 36999891) | insulin resistance | Not reported | Not reported | Not reported |
| Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. (PMID 37679692) | 2-hour oral glucose tolerance test (2 h-OGTT) | 10.44 ± 0.52 to 8.12 ± 0.40 mmol/L | p<10- 5 | 12 weeks |
| Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. (PMID 37679692) | Fasting insulin (FI) | 9.81 ± 0.36 to 7.88 ± 0.52 mmol/L | p<10- 5 | 12 weeks |
| Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. (PMID 37679692) | Glycosylated hemoglobin (HbA1c) | 6.40% ± 0.20-5.43% ± 0.21% % | p<10- 5 | 12 weeks |
| Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. (PMID 37679692) | Homeostatic model assessment-insulin resistance (HOMA-IR) | 3.61 ± 0.31 to 2.41 ± 0.14 | p<10- 5 | 12 weeks |
Study results, as reported by the publications
Every measured outcome, one row per finding - numbers exactly as reported. Units are preserved where supplied; missing units are not inferred.
| Study and type | Reported sample and duration | Outcome measured | Reported result | What studies found |
|---|---|---|---|---|
| PMID 36999891 2023 Systematic review | Sample (as reported): Not reportedDuration: Not reported | blood glucose levels | Not reported | Benefit |
| PMID 36999891 2023 Systematic review | Sample (as reported): Not reportedDuration: Not reported | blood lipids | Not reported | Benefit |
| PMID 36999891 2023 Systematic review | Sample (as reported): Not reportedDuration: Not reported | body parameters and composition | Not reported | Benefit |
| PMID 36999891 2023 Systematic review | Sample (as reported): Not reportedDuration: Not reported | colorectal adenomas | Not reported | Benefit |
| PMID 36999891 2023 Systematic review | Sample (as reported): Not reportedDuration: Not reported | gastrointestinal symptoms | Not reported | Harm / risk |
| PMID 36999891 2023 Systematic review | Sample (as reported): Not reportedDuration: Not reported | Helicobacter pylori infections | Not reported | Benefit |
| PMID 36999891 2023 Systematic review | Sample (as reported): Not reportedDuration: Not reported | inflammatory markers | Not reported | Benefit |
| PMID 36999891 2023 Systematic review | Sample (as reported): Not reportedDuration: Not reported | insulin resistance | Not reported | Benefit |
| PMID 30393248 2019 Meta-analysis | Sample (as reported): 2,313Duration: Not reported | fasting plasma glucose (FPG) | -0.54 mmol/L (95% CI: -0.77 to -0.30) | Benefit |
| PMID 30393248 2019 Meta-analysis | Sample (as reported): 2,313Duration: Not reported | postprandial plasma glucose (PPG) | -0.94 mmol/L (95% CI: -1.27 to -0.61) | Benefit |
| PMID 37679692 2023 Randomised trial | Sample (as reported): 34Duration: 12 weeks | 2-hour oral glucose tolerance test (2 h-OGTT) | 10.44 ± 0.52 to 8.12 ± 0.40 mmol/L (p<10- 5) | Benefit |
| PMID 37679692 2023 Randomised trial | Sample (as reported): 34Duration: 12 weeks | Fasting insulin (FI) | 9.81 ± 0.36 to 7.88 ± 0.52 mmol/L (p<10- 5) | Benefit |
| PMID 37679692 2023 Randomised trial | Sample (as reported): 34Duration: 12 weeks | Glycosylated hemoglobin (HbA1c) | 6.40% ± 0.20-5.43% ± 0.21% % (p<10- 5) | Benefit |
| PMID 37679692 2023 Randomised trial | Sample (as reported): 34Duration: 12 weeks | Homeostatic model assessment-insulin resistance (HOMA-IR) | 3.61 ± 0.31 to 2.41 ± 0.14 (p<10- 5) | Benefit |
Published research
Berberine × High blood sugar: the evidence base
Hand-selected PubMed studies, linked to the originals.
6studies referenced
6journals
2023–2026publication range
Ordered by strength of evidence, then result direction.
01Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysisXie K, et al. · Frontiers in psychiatry · 2026PMID 42433212 ↗02Clinical Efficacy of Curcumin, Resveratrol, Silymarin, and Berberine on Cardio-Metabolic Risk Factors Among Patients With Type 2 Diabetes Mellitus: A Systemic Review and Bayesian Network Meta-AnalysisMiao R, et al. · Phytotherapy research : PTR · 2025PMID 40439602 ↗03Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trialsLiu D, et al. · Frontiers in pharmacology · 2025PMID 40740996 ↗04The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled TrialsNazari A, et al. · Clinical therapeutics · 2024PMID 38016844 ↗05The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic reviewNie Q, et al. · Journal of translational medicine · 2024PMID 38429794 ↗06Effect of Fenugreek on Hyperglycemia: A Systematic Review and Meta-AnalysisShabil M, et al. · Medicina (Kaunas, Lithuania) · 2023PMID 36837450 ↗Community experiences
Contributors volunteered; this does not establish treatment effectiveness or population incidence.
Reported changes
No publishable community breakdown is available. This does not establish that no reports exist.
Important: This page reflects observational, aggregate-only community reporting and independent published research. It is not medical advice, and it does not claim any compound treats, cures, or is effective for any condition. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or treatment.